Synthex

SyntheX uses synthetic biology to create the next generation of drug discovery platforms. Using genetically engineered circuits, they rely on intracellular drug selection as opposed to in-vitro screening. This allows SyntheX to discover unbiased compounds with novel modes of action that can engage targets in either competitive or allosteric ways. They have developed ToRPPIDO to discover disruptors of protein-protein interactions (PPIs), and ToRNeDO to discover functional molecular glues for degraders of a neosubstrate of interest with a desired E3 ligase. In the same cells, SyntheX incorporates their proprietary DNA-encoded libraries of peptides and macrocycles to enable the production and selection of molecules in an efficient and high throughput manner. Their lead programs focus on oncology.